CHMP meeting highlights: February 2024
European Pharmaceutical Review
FEBRUARY 26, 2024
At its February 2024 meeting, the EMA’s human medicines committee (CHMP) recommended the extension of marketing authorisations for six treatments, and positive opinions for the approval of ten medicines. These products were designated as an orphan medicine during their development.
Let's personalize your content